Skip to content
Cultural Foundation
Author:
Tango Therapeutics Sub, Inc
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
June 9, 2026
Tango Therapeutics Announces Proposed $500 Million Public Offering
June 8, 2026
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
June 8, 2026
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 5, 2026
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 13, 2026
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
April 15, 2026